NDAINHALATIONGAS
Approved
Dec 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MEDICAL AIR, USP (medical air) by Connect Biopharma. Approved for idiopathic pulmonary fibrosis. First approved in 2016.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEDICAL AIR, USP is an inhaled gas product approved by the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Delivered via inhalation, it represents a non-traditional therapeutic modality in the IPF treatment landscape. The exact mechanism of action is not disclosed in available data.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30%), suggesting established market presence but requiring defensive strategies against well-funded competitors.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on MEDICAL AIR, USP at Connect Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.